临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 219861-08-2

Escitalopram Oxalate

中文名称:草酸右旋西酞普兰
CAS号:219861-08-2
分子式: C20H21FN2O.C2H2O4 分子量: 414.43
产品形式: Oxalate
研发状态: Not yet recruiting
研发用途: Opioid Induced Respiratory Depression; Depressive Disorder; Anxiety Disorders
研究机构: Leiden University Medical Center
研发日期: March 15 2023
研发阶段: Phase 1
Escitalopram Oxalate is a selective serotonin (5-HT) reuptake inhibitor (SSRI) with Ki of 0.89 nM.

CAS: 2192-20-3

Hydroxyzine 2HCl

中文名称:盐酸羟嗪
CAS号:2192-20-3
分子式: C21H27ClN2O2.2HCl 分子量: 447.83
产品形式: dihydrochloride
研发状态: Completed
研发用途: Smoking Cessation; Stress; Sleep Disturbance; Nausea
研究机构: Rose Research Center LLC; Foundation for a Smoke Free World INC
研发日期: June 17 2019
研发阶段: Phase 4
Hydroxyzine is a histamine H1-receptor antagonist, inhibits binding of [3H]pyrilamine/[3H]desloratadine to human histamine H1 receptor with IC50 of 10 nM/19 nM.

CAS: 21919-05-1

CB1954

中文名称:曲他齐卡
CAS号:21919-05-1
分子式: C9H8N4O5 分子量: 252.18
产品形式: free base
研发状态: Completed
研发用途: Prostate Cancer
研究机构: University of Birmingham; Janssen LP; Department of Health United Kingdom; Medical Research Council
研发日期: March 19 2013
研发阶段: Phase 1
CB1954 (Tretazicar, NSC 115829) is a anticancer prodrug that is converted in the presence of the enzyme NQO2 and co-substrate caricotamide ( EP-0152R) (EP) into a potent cytotoxic bifunctional alkylating agent. It can be activated by NAD(P)H quinone oxidoreductase 2.

CAS: 2189684-44-2

GS-6207

中文名称:HIV-1衣壳抑制剂GS-6207
CAS号:2189684-44-2
分子式: C39H32ClF10N7O5S2 分子量: 968.29
产品形式: chloride
研发状态: Active not recruiting
研发用途: HIV-1 Infection
研究机构: Gilead Sciences; Merck Sharp & Dohme LLC
研发日期: October 5 2021
研发阶段: Phase 2
GS-6207 (Lenacapavir) is a HIV-1 capsid inhibitor. It shows anti-HIV activity with an EC50 of 0.1 nM in MT-4 cells.

CAS: 218600-53-4

Bardoxolone Methyl

中文名称:甲基巴多索隆
CAS号:218600-53-4
分子式: C32H43NO4 分子量: 505.69
产品形式: free base
研发状态: Completed
研发用途: Chronic Kidney Disease; Type 2 Diabetes
研究机构: Kyowa Kirin Co. Ltd.
研发日期: Dec-14
研发阶段: Phase 2
Bardoxolone Methyl (RTA 402, TP-155, NSC 713200, CDDO Methyl Ester, CDDO-Me) is an IKK inhibitor, showing potent proapoptotic and anti-inflammatory activities; Also a potent Nrf2 activator and nuclear factor-κB (NF-κB) inhibitor. Bardoxolone Methyl abrogates ferroptosis. Bardoxolone methyl induces apoptosis and autophagy in cancer cells.

CAS: 218457-67-1

CB-103

中文名称:6-[4-(叔丁基)苯氧基]吡啶-3-胺
CAS号:218457-67-1
分子式: C15H18N2O 分子量: 242.32
产品形式: Free Base
研发状态: Recruiting
研发用途: Leukemia Lymphoblastic; Leukemia
研究机构: M.D. Anderson Cancer Center
研发日期: April 6 2023
研发阶段: Phase 2
CB-103 is an orally active inhibitor of the Notch transcription activation complex. CB-103 produces Notch loss-of-function phenotypes in flies and mice and inhibits the growth of human breast cancer and leukemia xenografts.